Corium Receives FDA Approval of ADLARITY (donepezil transdermal system) for Treatment of Patients with Alzheimer ' s Disease
BOSTON, March 14, 2022. Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced today the U.S. Food and Drug Administration (FDA) has...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Alzheimer's | Clinical Trials | Donepezil | Food and Drug Administration (FDA) | Pharmaceuticals